(HQL) Tekla Life Sciences - Ratings and Ratios
Biotechnology, Pharmaceuticals, Medical Equipment, Diagnostics
Dividends
| Dividend Yield | 12.93% |
| Yield on Cost 5y | 14.80% |
| Yield CAGR 5y | 1.87% |
| Payout Consistency | 85.1% |
| Payout Ratio | 65.2% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 19.7% |
| Value at Risk 5%th | 32.6% |
| Relative Tail Risk | 0.50% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.51 |
| Alpha | 28.28 |
| CAGR/Max DD | 0.73 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.416 |
| Beta | 0.650 |
| Beta Downside | 0.636 |
| Drawdowns 3y | |
|---|---|
| Max DD | 25.10% |
| Mean DD | 5.51% |
| Median DD | 4.82% |
Description: HQL Tekla Life Sciences December 29, 2025
Abrdn Life Sciences Investors (NYSE:HQL) is a closed-ended equity mutual fund that targets global public equities within the life-sciences ecosystem, ranging from biotech and pharma to medical devices and health-IT. The fund’s mandate emphasizes small-cap growth stocks, applying bottom-up fundamental analysis that weighs market positioning, management depth, technology moat, and capital-raising capability.
Key operational metrics (as of the latest filing) show an assets-under-management (AUM) of roughly $1.2 billion, an expense ratio of 0.85 %, and a 12-month total return of about +14 % versus the NASDAQ Biotech Index’s +9 % over the same period. The fund’s turnover rate hovers near 45 %, reflecting a moderate level of portfolio rebalancing consistent with its growth-orientation.
Sector-level drivers that underpin the fund’s thesis include: (1) a projected 6-7 % CAGR in global biotech R&D spend through 2028, (2) an aging-population tailwind that is expanding demand for specialty therapeutics and diagnostics, and (3) accelerating adoption of AI-enabled drug discovery, which is shortening development timelines for small-cap innovators.
Benchmarking is dual-fold: performance is measured against both the NASDAQ Biotech Index and the broader S&P 500, providing a relative gauge of sector-specific outperformance versus overall market trends.
Given the fund’s focus on capital-intensive, early-stage companies, its risk profile is sensitive to regulatory outcomes (e.g., FDA approvals) and financing conditions; a tightening credit environment could disproportionately affect the small-cap segment.
For a deeper quantitative view, you may want to explore ValueRay’s analytics platform to assess the fund’s risk-adjusted performance metrics.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (88.3m TTM) > 0 and > 6% of Revenue (6% = 1.45m TTM) |
| FCFTA -0.00 (>2.0%) and ΔFCFTA -0.20pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2.19% (prev -1.33%; Δ 3.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.00 (>3.0%) and CFO -1.04m <= Net Income 88.3m (YES >=105%, WARN >=100%) |
| Net Debt (-75.5k) to EBITDA (154.4m) ratio: -0.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.74 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.6m) change vs 12m ago 8.22% (target <= -2.0% for YES) |
| Gross Margin 57.04% (prev 85.17%; Δ -28.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 5.06% (prev 12.03%; Δ -6.97pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.79 (EBITDA TTM 154.4m / Interest Expense TTM 112.1m) >= 6 (WARN >= 3) |
Altman Z'' 50.70
| (A) 0.00 = (Total Current Assets 1.25m - Total Current Liabilities 720.9k) / Total Assets 515.4m |
| (B) 0.15 = Retained Earnings (Balance) 77.6m / Total Assets 515.4m |
| (C) 0.42 = EBIT TTM 200.4m / Avg Total Assets 478.7m |
| (D) 45.13 = Book Value of Equity 77.9m / Total Liabilities 1.73m |
| Total Rating: 50.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 60.38
| 1. Piotroski 2.50pt |
| 2. FCF Yield -0.21% |
| 3. FCF Margin -4.31% |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda -0.00 |
| 6. ROIC - WACC (= 30.63)% |
| 7. RoE 19.51% |
| 8. Rev. Trend 7.27% |
| 9. EPS Trend -51.32% |
What is the price of HQL shares?
Over the past week, the price has changed by -1.58%, over one month by -1.06%, over three months by +7.19% and over the past year by +44.42%.
Is HQL a buy, sell or hold?
What are the forecasts/targets for the HQL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 20.4 | 20.8% |
HQL Fundamental Data Overview January 14, 2026
P/S = 254.8518
P/B = 0.9617
Revenue TTM = 24.2m USD
EBIT TTM = 200.4m USD
EBITDA TTM = 154.4m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -75.5k USD (from netDebt column, last quarter)
Enterprise Value = 493.9m USD (494.0m + (null Debt) - CCE 75.5k)
Interest Coverage Ratio = 1.79 (Ebit TTM 200.4m / Interest Expense TTM 112.1m)
EV/FCF = -472.7x (Enterprise Value 493.9m / FCF TTM -1.04m)
FCF Yield = -0.21% (FCF TTM -1.04m / Enterprise Value 493.9m)
FCF Margin = -4.31% (FCF TTM -1.04m / Revenue TTM 24.2m)
Net Margin = 364.3% (Net Income TTM 88.3m / Revenue TTM 24.2m)
Gross Margin = 57.04% ((Revenue TTM 24.2m - Cost of Revenue TTM 10.4m) / Revenue TTM)
Gross Margin QoQ = 86.12% (prev -47.58%)
Tobins Q-Ratio = 0.96 (Enterprise Value 493.9m / Total Assets 515.4m)
Interest Expense / Debt = unknown (Interest Expense 30.7m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 158.3m (EBIT 200.4m * (1 - 21.00%))
Current Ratio = 1.74 (Total Current Assets 1.25m / Total Current Liabilities 720.9k)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.00 (Net Debt -75.5k / EBITDA 154.4m)
Debt / FCF = 0.07 (negative FCF - burning cash) (Net Debt -75.5k / FCF TTM -1.04m)
Total Stockholder Equity = 452.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 18.45% (Net Income 88.3m / Total Assets 515.4m)
RoE = 19.51% (Net Income TTM 88.3m / Total Stockholder Equity 452.6m)
RoCE = 38.93% (EBIT 200.4m / Capital Employed (Total Assets 515.4m - Current Liab 720.9k))
RoIC = 38.94% (EBIT 200.4m / (Assets 515.4m - Curr.Liab 720.9k - Cash 75.5k))
WACC = 8.31% (E(494.0m)/V(494.0m) * Re(8.31%) + (debt-free company))
Discount Rate = 8.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.03%
Fair Price DCF = unknown (Cash Flow -1.04m)
EPS Correlation: -51.32 | EPS CAGR: -40.90% | SUE: 0.71 | # QB: 0
Revenue Correlation: 7.27 | Revenue CAGR: -15.62% | SUE: N/A | # QB: 0
Additional Sources for HQL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle